The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pfizer, GSK vaccines could save nearly 1M lives by 2015

GlaxoSmithKline and Pfizer have pledged to supply vaccines against pneumococcal disease to the world's poorest countries at discounted prices. And the Global Alliance for Vaccines and Immunization,

Pfizer defends Neurontin as trial winds down

Pfizer defended Neurontin against a $270 million fraud claim as a trial wound down in Boston yesterday. One lawyer told the court that Neurontin is "a good drug that, at one time, at least in some

GSK, Pfizer discount vaccines for poor

Over the next 10 years, kids in developing countries will see a stream of discounted vaccines from Pfizer and GlaxoSmithKline. The two drugmakers have inked a long-term vaccine deal with the GAVI

Is Pfizer better off without Ratiopharm?

Losing Ratiopharm to Teva Pharmaceutical Industries may have made Pfizer a winner. That's the theory advanced by Motley Fool, which says that to outbid Teva, Pfizer would have had to overpay. And

Pfizer abandons Viagra suit against Lilly

Pfizer agreed to drop an 8-year-old patent infringement lawsuit against Eli Lilly over Viagra after a U.S. government agency rejected part of the male impotence drug's patent. Report

Teva comes out on top with $5B Ratiopharm bid

And the winner is... Teva. This morning, the generics giant announced that it was buying Ratiopharm for just under $5 billion, beating out Pfizer and Actavis for the German company. Ratiopharm is

Sources: Pfizer to place Ratiopharm bid today

It's coming down to the wire: Ratiopharm bids are due Thursday, and Reuters sources say Pfizer will come to the party early. The world's largest drugmaker is planning to submit its final bid for the

Roche, Pfizer cancer meds fail trials

Talk about a double whammy: Two big cancer drugs failed late-stage trials that could have broadened their use considerably. Roche's Avastin didn't make the grade against prostate cancer, failing to

Pfizer stops another figitumumab trial

Pfizer has discontinued another trial of its monoclonal antibody figitumumab. The drug was in a Phase III trial in combination with Tarceva as a second/third-line treatment for patients with

Supremes agree to take vaccines case

The U.S. Supreme Court has agreed to hear a suit pitting parents against vaccine makers. The case would determine whether federal law protects vaccine makers from liability lawsuits in state court.